MARKET

PALI

PALI

Palisade Bio Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.370
-0.080
-3.27%
Opening 15:22 09/28 EDT
OPEN
2.450
PREV CLOSE
2.450
HIGH
2.489
LOW
2.360
VOLUME
123.22K
TURNOVER
--
52 WEEK HIGH
16.02
52 WEEK LOW
2.270
MARKET CAP
27.01M
P/E (TTM)
-0.3697
1D
5D
1M
3M
1Y
5Y
BRIEF-Palisade Bio Files For Offer And Resale By Selling Stockholder Of Up To 1.9 Mln Shares
reuters.com · 4d ago
3 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Benzinga · 5d ago
Palisade Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
CARLSBAD, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, announces today that Chief Executive Officer Tom Hallam, Ph...
GlobeNewswire · 09/09 12:30
Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2021
Upgrades
Benzinga · 08/31 15:44
CRSR, XSPA and PALI among pre market gainers
AC Immune ACIU +71% after reporting mid-stage data for Alzheimer’s candidate Regional Health Properties (NYSE:RHE) +40%. Siyata Mobile  (NASDAQ:SYTA) +31%. Spok Holdings SPOK +22% on a buyout offer from Acacia Research for $10.75 per
Seekingalpha · 08/31 12:21
Maxim Group Initiates Coverage On Palisade Bio with Buy Rating, Announces Price Target of $7
Maxim Group analyst Naz Rahman initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy rating and announces Price Target of $7.
Benzinga · 08/31 12:05
--Maxim Starts Palisade Bio at Buy With $7 Price Target
MT Newswires · 08/31 07:41
BRIEF-Palisade Bio Says Cash And Cash Equivalents As Of June 30, 2021 Was $12.7 Mln, While Outstanding Debt Was $1.1 Mln
reuters.com · 08/24 12:28
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PALI. Analyze the recent business situations of Palisade Bio Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Price Target
The average PALI stock price target is 26.00 with a high estimate of 26.00 and a low estimate of 26.00.
High26.00
Average26.00
Low26.00
Current 2.370
EPS
Actual
Estimate
-2.82-2.12-1.41-0.71
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Institutional Holdings
Institutions: 44
Institutional Holdings: 2.51M
% Owned: 22.01%
Shares Outstanding: 11.40M
TypeInstitutionsShares
Increased
9
235.40K
New
7
2.13M
Decreased
8
4.32K
Sold Out
3
10.43K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.95%
Pharmaceuticals & Medical Research
-1.47%
Key Executives
Chairman/Director
James Neal
President/Chief Operating Officer
Matthew Kalnik
Chief Executive Officer/Chief Financial Officer/Chief Accounting Officer
Dane Saglio
Chief Executive Officer/Director
Thomas Hallam
Director
Stephanie Diaz
Director
Robert Trenschel
Director
Don Williams
Independent Director
Cristina Csimma
Independent Director
Mary Gray
Independent Director
Binxian Wei
No Data
About PALI
Palisade Bio, Inc, formerly Seneca Biopharma, Inc., is a biopharmaceutical company. The Company is focused on developing therapies that helps patients with acute and chronic gastrointestinal problems from post-operative digestive enzyme damage. Its product candidate, LB1148, is a Phase III-ready protease inhibitor which is developed to reduce abdominal adhesions and help restore bowel function following surgery. It is engaged in developing oral product candidates to treat conditions driven by protease (intestinal digestive enzymes) escaping the intestines, including surgical problems and inflammatory conditions. Its LB1148 is an oral formulation of a serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery.

Webull offers kinds of Palisade Bio Inc stock information, including NASDAQ:PALI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PALI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PALI stock methods without spending real money on the virtual paper trading platform.